Recombinant Lipoprotein Technology in Cancer Immunotherapy
Recombinant Lipoprotein Technology in Cancer Immunotherapy
Targeted indication
HPV-associated cancer
Status
Preclinical
Key features
- High safety profile
- Highly immunogenic protein
- The platform technology could be applied to different vaccine products.
Market
The fusion protein made using this technology can be alone as a vaccine candidate or mixed with a carrier, such as an adjuvant, in vaccines or as a medicament for immune modulation.
In vaccination, subunit vaccines are likely the new generation vaccines because of their safety and efficiency. This technology has been applied in meningococcal group B subunit vaccine (MGBvac), dengue subunit vaccine, and HPV-based immunotherapeutic vaccines.
We expect this technology to be used in the development of new and better vaccines, especially for the unmet medical need disease areas.
MODE OF ACTION
Recombinant lipoprotein can trigger both innate and adaptive immunity.
EXPERIMENTAL RESULTS
Induction of dendritic cells activation through TLR2.
Inhibition of large tumor growth.
Non-toxic in Single Dose Acute Toxicity Testing (At doses up to 10 times of the effective dose in animal).
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
1. Chang et al. OncoImmunology. 5: e1095433, 2016
2. Shen et al. Expert Rev Vaccines 2015, 14(3):383-94
3. Chang et al. Mol. Cancer. 2014, 13:60
4. Huang et al. PLoS ONE 7: e40970. 2012
5. Leng et al. Mol. Immunol. 47: 2015-2021 (2010)
6. Chen et al. Vaccine 27:1400-9 (2009)
BUSINESS OPPORTUNITY
License out and/or Collaboration and Sponsored Research
CONTACT
service@biip-dcc.org